Alzheimer’s & Dementia Care
-
Daily Alzheimer’s pill slows brain shrinkage, boosts cognition
The recent findings, unveiled at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2026) in Copenhagen, represent a…
Read More » -
FDA Approves Auvelity as the First Non-Antipsychotic Treatment for Agitation Associated with Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel therapeutic option for the…
Read More » -
Alzheimer’s and Brain Awareness Month 2024: A Global Call to Action for Research and Cognitive Health
June serves as a critical junction for the global medical community and the millions of families affected by neurodegenerative conditions,…
Read More » -
Real-world study of Zunveyl reveals promising provider-reported outcomes for Alzheimer’s patients in long-term care settings
Top-line results from the BEACON real-world study have shed new light on the clinical utility of Zunveyl (benzgalantamine), an oral…
Read More » -
FDA designation may speed new treatment for Alzheimer’s psychosis
The U.S. Food and Drug Administration (FDA) has officially granted Fast Track designation to remlifanserin, an investigational therapeutic agent currently…
Read More » -
Patients can now skip infusions at hospital during early treatment for Alzheimer’s disease as the therapeutic landscape shifts toward at-home care.
In a landmark development for neurology and patient care, the U.S. Food and Drug Administration (FDA) has expanded the authorization…
Read More » -
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically for…
Read More » -
June: A Pivotal Month for Alzheimer’s and Brain Awareness, Catalyzing Research and Action Against a Global Health Challenge
June marks a critical period for global public health as the Alzheimer’s Association spearheads Alzheimer’s & Brain Awareness Month, a…
Read More » -
Zunveyl (benzgalantamine) Associated with Provider-Reported Improvements in Alzheimer’s Patients in Real-World Study
Top-line data from the BEACON study, a real-world observational study, indicate that Zunveyl (benzgalantamine) was associated with provider-reported improvements across…
Read More » -
Real-World BEACON Study Highlights Zunveyl’s Positive Impact on Alzheimer’s Patients in Long-Term Care, Paving Way for Further Research
Top-line data from the BEACON study, a significant real-world investigation, suggest that Zunveyl (benzgalantamine) was associated with notable improvements across…
Read More »
